Bioheart (OTCMKTS:USRM) and Immunovant (NASDAQ:IMVT) Critical Comparison

Bioheart (OTCMKTS:USRM) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Valuation and Earnings

This table compares Bioheart and Immunovant”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioheart	N/A	N/A	N/A	N/A	N/A
Immunovant	N/A	N/A	-$505.61 million	($2.78)	-11.22

Profitability

This table compares Bioheart and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioheart	N/A	N/A	N/A
Immunovant	N/A	-65.66%	-59.88%

Volatility and Risk

Bioheart has a beta of -0.99, indicating that its share price is 199% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Bioheart and Immunovant, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioheart	0	0	0	0	0.00
Immunovant	1	4	6	0	2.45

Immunovant has a consensus price target of $37.33, indicating a potential upside of 19.73%. Given Immunovant’s stronger consensus rating and higher probable upside, analysts plainly believe Immunovant is more favorable than Bioheart.

Insider and Institutional Ownership

47.1% of Immunovant shares are held by institutional investors. 16.7% of Bioheart shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Immunovant beats Bioheart on 5 of the 8 factors compared between the two stocks.

About Bioheart

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.